The gadget that first went viral when Zomato founder Deepinder Goyal appeared wearing it on a podcast is inching closer to becoming an actual commercial product and the price being discussed is not for the faint-hearted. Temple, the brain-monitoring wearable startup that Goyal founded after stepping down as CEO of Eternal, is reported to be considering a price of approximately ₹72,000 for its device, placing it firmly in the premium bracket that has historically belonged to specialised medical equipment rather than consumer wearables.
The price has emerged from early conversations among investors and early adopters following Temple’s progress as it transitions from limited early access to a commercial product approach. Temple’s price of ₹72,000 surpasses even premium consumer wearables in the Indian market, such as the Apple Watch Ultra, which costs roughly ₹89,000, while Oura Ring and WHOOP are more affordable subscription-based options. However, Temple is not competing with those products. It is seeking to define a totally new category.
“The small white round device attached near the temple on the face is a wearable brain-monitoring device, which can cost anywhere between ₹70,000 and ₹1,00,000.”~IPO Investor Academy
What Temple Actually Measures And The Science Behind It:
The purpose of Temple’s technology is to continually evaluate cerebral blood flow, or the efficiency with which blood reaches various brain regions throughout daily activities, physical activity, work, and sleep. What sets Temple’s value proposition apart from heart rate monitors, sleep trackers, and activity bands is this physiological measure, which no consumer wearable in the world presently captures with any meaningful precision.
The scientific framework the company has built around the device traces back to what Goyal calls the Gravity Ageing Hypothesis. The theory proposes that Earth’s gravity, acting consistently over a lifetime of upright posture, gradually makes it harder for blood to circulate upward to the brain. Over decades, this reduced cerebral circulation may contribute to cognitive decline, accelerated ageing, and decreased mental performance particularly affecting regions like the hypothalamus and brainstem that regulate core biological functions.
Goyal has been transparent that this is not yet mainstream science. He stated clearly: “We haven’t made any public commercial announcements about Temple yet. We haven’t released any official device benchmarking data.” The company is still in the early access testing phase, with the first 100 devices shipped to a carefully selected group of athletes, scientists, doctors, and founders in May 2026.
“Hello world. The first 100 Temples are ready to ship. We’re now inviting athletes, scientists, founders, doctors, creators, and individuals who care deeply about their physical and cognitive health to be the founding users of Temple. Apply for early access at…”~Deepinder Goyal
$54 Million Raised, 80-Plus Investors, 30 Employees Invested Their Own Money:
After raising $54 million in its first significant fundraising round, Temple is now valued at about $190 million. Along with over 80 individual investors, Peak XV Partners, Steadview Capital, Vy Capital, Info Edge Ventures, and Dharana Capital participated in the round. Goyal himself pointed out that over thirty Temple workers took part at the same price as outside investors without any special stipulations. This was an uncommon display of internal confidence.
Goyal has personally invested approximately $25 million into Continue Research, the longevity science initiative from which Temple emerged meaning his total personal exposure to the venture goes well beyond what the fundraise discloses. His broader investment thesis which also includes LAT Aerospace and Continue Research, reflects a pattern of moving from building consumer businesses to backing the kind of deep science and hard technology companies that most venture capital avoids.
“Friends and family. $54m. Post-money valuation of ~$190m. Every investor in this round is a founder friend or early-stage Zomato investor who wanted in, whether or not Temple ever makes it to market. But here’s what gives me goosebumps…”~Deepinder Goyal
Scepticism From Doctors, No FDA Clearance, But A Genuinely Novel Problem:
The invention has received intense scientific scrutiny. In a public statement regarding Temple, neurologist Dr Sudhir Kumar stated that successfully monitoring deep-brain blood flow signals using a skin-mounted sensor near the temple poses fundamental physiological problems concerning signal depth and accuracy. Medical specialists have also pointed out that, while academically intriguing, the Gravity Ageing Hypothesis reduces a highly complicated biological process to a single physical force, an oversimplification that would require rigorous clinical validation before any medical claims could be made.
Temple has received no FDA permission, no published clinical study results, and no regulatory approval in India or abroad. The company has made no claims regarding the device’s medical diagnostic capabilities. Temple is positioned as a research and performance tool rather than a medical equipment, which is important for regulatory concerns as well as user expectations.
Despite the doubts, the category Temple is entering into continuous, real-time cerebral monitoring outside a clinical setting is genuinely without a commercial equivalent. Whether the device can deliver on that promise at a ₹72,000 price point, and whether that price will find sufficient buyers among the elite athlete and performance-focused professional demographic Temple is targeting, are the two open questions that the coming months will begin to answer.
